Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by <em>Enterobacteriaceae</em>
In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for <i>Enterobacteriaceae</i> from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP brea...
Saved in:
Main Authors: | Ga Eun Park (Author), Jae-Hoon Ko (Author), Sun Young Cho (Author), Hee Jae Huh (Author), Jin Yang Baek (Author), Kwan Soo Ko (Author), Cheol-In Kang (Author), Doo Ryeon Chung (Author), Kyong Ran Peck (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant <i>Staphylococcus aureus</i>: A Time-Kill Assay
by: Yu Ri Kang, et al.
Published: (2023) -
Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
by: Ching-Chi Lee, et al.
Published: (2019) -
Pharmacokinetic/pharmacodynamic based dosing of ciprofloxacin in complicated urinary tract infections
by: Ana Sabo, et al.
Published: (2015) -
Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis
by: Dehong Cao, et al.
Published: (2021) -
Fosfomycin Resistance in <i>Escherichia coli</i> Isolates from South Korea and <i>in vitro</i> Activity of Fosfomycin Alone and in Combination with Other Antibiotics
by: Hyeri Seok, et al.
Published: (2020)